Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Martinez M
  • Rabadan S
  • Domingo J
  • Cobo A
  • Garcia-Velasco JA

Grupos

Abstract

Obstetric outcome of first pregnancies achieved after vitrification and warming oocytes from women being treated for cancer was evaluated. Of a total of 493 women who consulted for fertility preservation 357 had their oocytes cryopreserved after being diagnosed with cancer and 11 returned after being cured for assisted reproduction treatments (eight had breast cancer one Hodgkin lymphoma one endometrial adenocarcinoma and one thyroid cancer). The oocyte survival rate was 92.3% the fertilization rate was 76.6% and the mean number of embryos transferred was 1.8 +/- 0.7. Beta-human chorionic gonadotropin was detected in seven out of the 11 embryo transfers carried out. Four ongoing pregnancies were achieved and delivered at term with normal fetal weight and no major or minor malformations. Women diagnosed with cancer who have their eggs cryopreserved before anti-cancer treatment have good assisted reproductive technology performance and good perinatal outcomes. Cryopreservation of oocytes seems to be a good alternative for fertility preservation in these women. (C) 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1472-6483, 1472-6491

REPRODUCTIVE BIOMEDICINE ONLINE  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
722-728
Factor de Impacto:
1,466 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 72

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • fertility preservation; oocyte; perinatal outcome; vitrification

Campos de estudio

Proyectos asociados

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORRELL

CD11/00292 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

CONTRATO POSTDOCTORAL DE INVESTIGACION SARA BORELL

CD12/00568 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

CONTRATO POST FSE (RIO HORTEGA)

CM13/00191 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, PARA EVALUAR SEGURIDAD Y EFICACIA DE ELAGOLIX EN PARTICIPANTES CON DOLOR MODERADO O SEVERO ASOCIADO A ENDOMETRIOSIS.

Investigador Principal: VICENTE PAYÁ AMATE

M12-671

Cita

Compartir